Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BBOX1 antisense RNA 1 (BBOX1-AS1)
- Target
- BBOX1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA, Other
01
Overview
BBOX1 antisense RNA 1 (BBOX1-AS1) is a long non-coding RNA gene located on chromosome 11 (p14.2–p14.1), transcribed antisense to BBOX1. It consists of 7 exons and produces several splice variants. BBOX1-AS1 is markedly upregulated in a wide spectrum of cancers originating from different systems and is associated with oncogenic functions, including promoting cell proliferation, migration, invasion, and metastasis while inhibiting apoptosis. Mechanistically, BBOX1-AS1 exerts its regulatory effects through ceRNA mechanisms (sponging multiple cancer-relevant miRNAs), stabilizing oncogenic mRNAs, and modulating critical cancer signaling pathways. Its expression correlates with tumor progression, metastasis, and poor prognosis, and it serves as a novel biomarker for diagnosis and prognosis in several human cancers.
- Other names
- BBOX1-AS1Gamma-butyrobetaine hydroxylase 1 antisense RNA 1ENSG00000254560lncRNA BBOX1-AS1
02
Mechanism of action
Acts as a competitive endogenous RNA (ceRNA), sponging tumor-suppressive microRNAs (miRNAs) to regulate expression of target genes. Regulates mRNA stability of certain oncogenes or key signaling proteins. Modulates diverse cancer-related signaling pathways (e.g., Hedgehog, Wnt/β-catenin, MELK/FAK).
03
Biological functions
Regulation of cell growthEpithelial–mesenchymal transitionCell migrationCell invasionMetastasisRegulation of cell death/apoptosisRegulation of stemnessRegulation of gene expression (via ceRNA network/miRNA sponging and mRNA stabilization)
04
Disease associations
CancerTumorigenesisTumor prognosis and diagnosis (notably in lung cancer, esophageal cancer, oral cancer, pituitary adenoma, gastric cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer)
05
Safety considerations
No specific therapeutic safety concerns reported; as a non-coding RNA, off-target or delivery challenges are general issues for RNA-targeted therapies.
06
Biomarkers
BBOX1-AS1 expression level (predictive and diagnostic biomarker in multiple cancers, including lung and esophageal carcinoma)
Beyond the preview
Go deeper on BBOX1 antisense RNA 1 (BBOX1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBOX1 antisense RNA 1 (BBOX1-AS1).